Andira

Vancouver, Canada Founded: 2020 • Age: 6 yrs
Digital pharmacotherapeutic platform for providers

About Andira

Andira is a Healthcare company based in Vancouver (Canada) founded in 2020 by Dana Lambert. Digital pharmacotherapeutic platform for providers. Andira has raised $1.81 million across 9 funding rounds. Its chief executive, as recorded, is Dana Lambert. Andira offers products and services including Silvanexâ„¢ Flex, Silvanexâ„¢ IV Site, Silvanexâ„¢ Topical, AND-259, and AND-254. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery.

Company details

Andira was founded in 2020 in Vancouver, Canada, as a digital pharmacotherapeutic platform targeted at healthcare providers. Operations center on the identification and development of natural compounds that hold potential for therapeutic applications. Services include tools for chemical discovery and pharmacotherapeutic support, with a focus on integrating natural substances into medical practices across the biotechnology sector.

  • Headquarters Vancouver, Canada
  • Founders Dana Lambert
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website andira.ca
  • Social LinkedIn
Key Metrics
  • Total Equity Funding
    $1.81M (USD)

    in 9 rounds

  • Latest Funding Round
    $120K (USD), Series A

    Sep 2026

Products & Services of Andira

Andira offers a comprehensive portfolio of products and services, including Silvanex™ Flex, Silvanex™ IV Site, Silvanex™ Topical, AND-259, and AND-254.

Silvanex™ Flex
Medical Device

Provides advanced wound care using cannabinoid technology

Silvanex™ IV Site
Medical Device

Prevents infections at IV insertion sites

Silvanex™ Topical
Therapeutics

Treats surgical site infections with cannabinoids

AND-259
Therapeutics

Targets breast cancer through cannabinoid-based innovation

AND-254
Therapeutics

Addresses mastectomy pain via therapeutic development

Funding Insights of Andira

Andira has successfully raised a total of $1.81M across 9 strategic funding rounds. The most recent funding activity was a Series A round of $120 thousand completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.81M
  • Total Rounds 9
  • Last Round Series A — $120,000
  • First Round $393,084

    (Mar 2022)

All 9 funding rounds of Andira with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2026Debt – Conventional––
–
Sep 2026$120,000Series A––
–
Aug 2026$100,000Seed––
–
Aug 2026Debt – Conventional––
–
Feb 2026$152,390Seed––
–
Aug 2024$809,922Seed––
–
Jun 2024$18,281Seed––
–
Oct 2023$212,008Seed––
–
Mar 2022$393,084Seed––
–

People of Andira

12 people are tracked at Andira (4 in leadership, 4 in board & advisors, 4 in team).

NameRoleGroup
Dana Lambert
Founder & CEOLeadership
Janette Lyons
CFOLeadership
Evelina Rubinchik
Chief Scientific OfficerLeadership
Ethan Russo
Chief Medical OfficerLeadership
Mark Loveless
AdvisorBoard & advisors
Ryan Miller
AdvisorBoard & advisors
Julia Levy
AdvisorBoard & advisors
Kishor Wasan
AdvisorBoard & advisors
Nishi Whiteley
Manager, Communications & Special ProjectsTeam
Claudia H. Dietrich
Research ScientistTeam
Michael Wall
Administrative OfficerTeam
Curtis Harwig
Manager, Product Manufacture & CMCTeam
Premium access

Complete people profiles for Andira

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Andira

3 dated milestones of Andira across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Andira is founded.
  2. Funding First funding round of $393K.
  3. Funding Latest funding round, Series A, of $120K.

Web traffic of Andira

The website of Andira (andira.ca) receives about 4.7K visits a month.

  • Monthly visits
    4.7K

    ▲ 1192.3% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Andira

Premium access

Complete news archive for Andira

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Andira

Andira was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Andira is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.

Dana Lambert is the CEO of Andira, as recorded in our data. They have also founded this company.

Andira is a funded company, having raised a total of $1.81M across 9 funding rounds to date. The company's 1st funding round was a Seed of $393.08K, raised on Mar 2022.

Andira was founded in 2020 in Vancouver, Canada, as a digital pharmacotherapeutic platform targeted at healthcare providers. Operations center on the identification and development of natural compounds that hold potential for therapeutic applications. Services include tools for chemical discovery and pharmacotherapeutic support, with a focus on integrating natural substances into medical practices across the biotechnology sector.

Andira offers Silvanexâ„¢ Flex, Silvanexâ„¢ IV Site, Silvanexâ„¢ Topical, AND-259, and AND-254.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available